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SUMMARY
1. In this minireview we address the predictive value of
blood pressure variability, over and beyond level of pressure, in
randomly selected population samples. All reviewed studies had
sufficient power, long follow-up duration and a wide age range.
2. We assessed blood pressure variability derived from
home visit, self-measured home pressure and 24 h ambulatory
monitoring. The conclusions are based mainly on novel indices
of blood pressure variability: variability independent of the
mean, difference between maximum and minimum blood
pressure and average real variability.
3. None of these variability indices or morning surge in
blood pressure substantially refined risk profiling over and
beyond the blood pressure level.
4. In risk stratification, clinicians should concentrate on
blood pressure level, the predominant risk factor modifiable
by lifestyle measures and antihypertensive drug treatment.
Key words: average real variability, blood pressure
variability, epidemiology, general population, risk factors,
variability independent of the mean index.
INTRODUCTION
The prognostic significance of blood pressure variability (BPV)
remains contentious. Some studies have reported associations
between BPV and end-organ damage,1–4 cardiovascular events5–7
or mortality8, whereas others failed to do so or found variability to
be inferior to mean systolic pressure.9–11 Whether naturally
occurring BPV predicts risk over and beyond blood pressure level
remains uncertain.
Recent publications12,13 suggest that clinicians may reduce
stroke risk more effectively by targeting systolic blood pressure
(SBP) variability along with SBP level using specific classes of
antihypertensive drugs. These recommendations12,13 originated
mainly from clinical trials, which included high-risk groups, such
as elderly14,15 or hypertensive16 patients or participants with a
previous ischaemic stroke or transient ischaemic attack14 or
diabetes mellitus.15,17 Other methodological issues that may have
introduced bias are non-randomization, possible lack of
power,5,17 short follow-up time,17 categorization of continuous
variability measures for risk prediction,8,14 the use of variability
measures that are dependent on the level of blood pressure,8,15
limited adjustment14 or failure to
account for reverse causality.18 These
factors render the current evidence on
the prognostic significance of BPV
inconclusive, especially in the general
population.
In this minireview we address the predictive value of BPV,
over and beyond level of pressure, in randomly selected
population samples. All reviewed studies had sufficient power,
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long follow-up duration and a wide age range. In addition, the
conclusions are based mainly on novel indices of BPV, as
assessed by conventional sphygmomanometry, self-measurement
at home or 24 h ambulatory monitoring.
MEASURES OF BPV
Historical perspective
In the early 1970s, Clement et al.19 assessed variability from the
standard deviation (SD) and coefficient of variation (CV) of blood
pressure measurements obtained every 5 min for 3 h in 70
untreated hypertensive patients. In that study, a positive
relationship between sympathetic activity and the SD of blood
pressure was observed. Blood pressure level and SD were also
correlated. The CV was not correlated with various indices of
sympathetic activity. In the early 1980s, Mancia et al.20,21 analysed
24 h continuous intra-arterial recordings and showed that SD was
positively correlated with blood pressure level and fell with
antihypertensive drug treatment, whereas CV was independent of
level irrespective of drug intervention.21 Notwithstanding these
initial findings, the same group used SD rather than CV to estimate
the association between BPV and target organ damage on the
incidence of cardiovascular complications.22,23 These results were
biased by blood pressure level.22,23
New indices of BPV
Recently Mena et al.24 proposed average real variability (ARV)
as a novel index representing short-term, reading-to-reading,
within-subject variability in blood pressure. The ARV attempts to
correct for the limitations of the commonly used SD, which
accounts only for the dispersion of values around the mean and
not for the order of the blood pressure readings.11,24,25 The ARV
is calculated by the following formula:
ARV ¼ 1P
w
Xn1
k¼1
w BPk1j BPkj
where k ranges from 1 to n – 1, w is the time interval between
BPk and BPk+1 and n is the number of blood pressure readings.
Rothwell et al. proposed BPV independent of the mean (VIM)
as a new index,12,14 which may be a better predictor of
cardiovascular outcome. The blood pressure VIM12,14 is
calculated as the SD divided by the
mean to the power x and multiplied by
the population mean to the power x. The
power x is obtained by fitting a curve
through a plot of SD against mean using
the model SD = a 9 meanx, where x
was derived by non-linear regression analysis.
Finally, some investigators also proposed maximum minus
minimum blood pressure (MMD) as an index of BPV.26,27
VARIABILITY OF CONVENTIONAL BLOOD
PRESSURE
We investigated the predictive value of BPV in a family-based
randomly selected representative sample from the general
population in Belgium with sufficient power, follow-up time and
a wide age range (n = 2944; mean age 44.9 years; 50.7%
women).28 At baseline, trained nurses measured each
participant’s blood pressure at two home visits at an interval of
2–4 weeks. At each home visit, after the participants had rested
for 5 min in the sitting position, the nurses obtained five
consecutive blood pressure readings to the nearest 2 mmHg
using mercury sphygmomanometers. We implemented a stringent
programme for quality assurance and quality control. Every
3 months, the observers had to pass a test requiring them to read
blood pressures from a videotape featuring a falling mercury
column with Korotkoff sounds. Their readings had to comply
within 5 mmHg of those of senior medical staff. Digit preference
was checked at 6 monthly intervals.
We assessed within-subject overall (10 readings), within- and
between-visit systolic BPV from VIM, MMD and ARV. Over a
median follow up of 12 years, 401 deaths occurred and 311
participants experienced a fatal or non-fatal cardiovascular event.
Overall mean ( SD) systolic BPV was 5.45  2.82 units,
15.87  8.36 mmHg and 4.08  2.05 mmHg for VIM, MMD
and ARV, respectively. Female gender, older age, higher mean
SBP, lower body mass index, a history of peripheral arterial
disease and the use of beta-blockers were the main correlates of
systolic BPV. In multivariable-adjusted analyses, overall and both
within- and between-visit BPV did not predict total or
cardiovascular mortality or the composite of any fatal plus non-
fatal cardiovascular end-points. For example, the hazard ratios
(HR) for all cardiovascular events combined in relation to overall
VIM, MMD and ARV were 1.05 (95% confidence interval (CI),
“New indices
of blood
pressure
variability”
List of abbreviations:
ARV average real variability
BPV blood pressure variability
MMD difference between maximum and minimum blood pressure
VIM variability independent of the mean
© 2013 Wiley Publishing Asia Pty Ltd
2 K Asayama et al.
0.96–1.15), 1.06 (95% CI 0.96–1.16), and 1.08 (95% CI 0.98–
1.19), respectively. In contrast, mean SBP was a significant
predictor of all end-points under investigation, independent of
BPV (Fig. 1). In conclusion, in an unbiased population sample,
BPV derived from conventional blood pressure readings did not
contribute to risk stratification over and beyond mean SBP.28
VARIABILITY OF SELF-MEASURED BLOOD
PRESSURE
Self-measured home blood pressure offers several of the well-
recognised advantages of the more complex approach of
ambulatory monitoring.29–31 The greater number of readings and
the minimisation of the white coat effect, observer bias and
measurement error all contribute to a better diagnostic accuracy
compared with office blood pressure measurement. Similar to
visit-to-visit variability in the conventional clinic blood
pressure,14 multiple home blood pressure measurements32–34
provide information on the day-to-day BPV in the relatively
controlled home environment.
In 2008, we assessed self-measured home BPV in the
Ohasama population, using the within-subject SD of the morning
SBP over 26 days (median) of self-measurement.34 In
multivariable-adjusted Cox models also including blood pressure
level, a 1 – SD increase in the between-subject variability was
associated with a higher risk of total mortality (HR 1.18; 95%
CI, 1.07–1.31), cardiovascular mortality (HR 1.20; 95% CI 1.02–
1.40), non-cardiovascular mortality (HR 1.18; 95% CI 1.04–1.34)
and stroke mortality (HR 1.38; 95% CI 1.12–1.72), but not
cardiac mortality (HR 1.02; 95% CI 0.81–1.29). Cardiac
mortality included deaths from coronary heart disease and heart
failure. Cardiovascular mortality comprised the aforementioned
end-points plus fatal stroke. The association of BPV with non-
cardiovascular mortality was difficult to interpret, but may reflect
reverse causality, subclinical disease leading to greater variability.
More recently, the Finn-Home investigators reported that day-
to-day variability of the self-measured SBP in the morning,
estimated from the within-participant SD over 7 days, predicted
total mortality and cardiovascular events.6 The HR expressing
incremental risk of total mortality and cardiovascular events for a
1 mmHg between-subject increment in
variability was 1.05 (95% CI 1.02–1.09;
P = 0.006) and 1.04 (95% CI 1.00–
1.07; P = 0.03), respectively.6 Day-to-
day variability in the evening SBP was
not predictive (P ≥ 0.11).6 Ushigome
et al. showed significant correlations
between CV of self-measured home blood pressure and
macroalbuminuria in Type 2 diabetes mellitus.35 However, SD,
CV and ARV of self-measured home blood pressure did not
predict the progression of chronic kidney disease reported by
Okada et al.36
We explored whether new indices of BPV derived from the
self-measured home blood pressure predicted outcome.37 We
analysed mortality and stroke risk in 2421 Ohasama residents
and excluded high-risk subjects with a previous stroke. In the
Ohasama study, physicians and public health nurses instructed
participants how to measure their home blood pressure using a
validated oscillometric device (OMRON HEM 401C; Omron
Healthcare, Kyoto, Japan). Participants were asked to record their
blood pressure for 4 weeks: (i) after at least 2 min rest in the
morning within 1 h of waking and, if applicable, before taking
their blood pressure-lowering medications; and (ii) in the evening
just before going to bed. The first reading obtained on each
occasion was used for analysis. We assessed the independent
predictive value of the within-subject mean SBP and
corresponding variability as estimated by variability independent
of the mean (VIM), difference between maximum and minimum
blood pressure (MMD) and ARV. Over a median of 12.0 years,
412 participants died (139 of cardiovascular causes) and 223 had
a stroke. In multivariable-adjusted Cox models including morning
systolic pressure: (i) VIM and ARV predicted total and
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Fig. 1 Absolute 10 year risk of (a) death and (b) cardiovascular events
in relation to mean systolic blood pressure (SBP) at different levels of
overall systolic variability independent of the mean (VIM).28 Mean SBP
along the x-axis covers the 5th–95th percentile interval. The VIM is
presented by four risk functions corresponding with 2, 4, 6 and 9 units
(approximate quartile mid-points). The risk functions were standardized to
the distributions (mean or ratio) of sex, age, body mass index, heart rate,
smoking and drinking, total : high-density lipoprotein serum cholesterol
ratio, plasma glucose, history of cardiovascular disease and the use of
beta-blockers. Among 2944 participants, 401 deaths and 311 composite
cardiovascular end-points occurred. PSBP and PVIM indicate the
significance of mean SBP and the overall VIM. Reproduced with
permission from Schutte et al.28
“Variability of
self-measured
blood
pressure”
© 2013 Wiley Publishing Asia Pty Ltd
Risk of blood pressure variability 3
cardiovascular mortality in all participants (P ≤ 0.044); (ii) VIM
predicted cardiovascular mortality in treated (P = 0.014), but not
in untreated (P = 0.23) participants; and (iii) morning MMD did
not predict any end-point (P ≥ 0.085). In models already
including evening systolic pressure, only VIM predicted
cardiovascular mortality in all and in untreated participants
(P ≤ 0.046). Figure 2 shows the multivariable-adjusted 10-year
risk of a cardiovascular death in relation to the mean level and
VIM of morning SBP in all participants. Morning SBP was a
consistent predictor of stroke and cardiovascular mortality
(P ≤ 0.0049), with the exception of cardiovascular mortality in
treated participants (P = 0.082).
The R2 statistic, a measure of the incremental risk explained
by adding BPV to models already including SBP and
covariables, ranged from < 0.01% to 0.88%. In conclusion, in a
Japanese population, the new indices of BPV derived from self-
measured home blood pressure did not incrementally predict
outcome over and beyond mean systolic pressure. Being on
antihypertensive drug treatment seemed to be the main driver of
the significant associations between cardiovascular mortality and
BPV.37
VARIABILITY OF AMBULATORY PRESSURE
Sleep–trough and pre-awakening morning surge
Kario et al.38 introduced the definitions of the sleep–trough and
pre-awakening morning surge in blood pressure. They compared
the risk of silent and clinical cerebrovascular diseases in 53
hypertensive (assessed by clinic measurement) patients of the top
decile (≥ 55 mmHg) of the systolic sleep–trough morning surge
with the risk in the other 466 patients. The risk of multiple brain
infarcts was approximately twofold higher in patients belonging
to the top decile of the systolic sleep–trough morning surge. The
morning surge remained a significant predictor of stroke even
after adjustment for the 24 h blood pressure, nocturnal dipping
status and the prevalence of silent infarcts at enrolment.38
However, these findings are not supported by the recent
publication by Verdecchia et al.39 who investigated the
relationship between the day–night
blood pressure dip and the early
morning surge in a cohort of 3012
initially untreated subjects with essential
hypertension. In that population, the
magnitude of blood pressure dip from
day to night (night-to-day ratio) was directly associated with the
magnitude of the blood pressure surge in the early morning; the
day–night reduction in SBP showed a direct association with the
sleep–trough (r = 0.564; P < 0.0001) and the pre-awakening
(r = 0.554; P < 0.0001) SBP surge.39 Over a mean follow-up
period of 8.44 years, 268 subjects had a cardiovascular event and
220 subjects died. A blunted sleep–trough (≤ 19.5 mmHg; the
lowest quartile) and pre-awakening (≤ 9.5 mmHg) blood pressure
surge were both associated with an excess risk of events (HR
1.66 (95% CI 1.14–2.42) and 1.71 (95% CI 1.12–2.71),
respectively). However, neither patients with a high sleep–trough
(> 36.0 mmHg; the highest quartile) nor those with a high pre-
awakening (> 27.5 mmHg) systolic pressure had independent
risks for mortality and cardiovascular events.
We analysed the sleep–trough and the pre-awakening morning
surge in the International Database on Ambulatory blood pressure
monitoring in relation to Cardiovascular Outcomes (IDACO)
study,40 a large randomly recruited population sample from 11
centres.11,40–42 We programmed portable monitors to obtain
ambulatory blood pressure readings at 30 min intervals
throughout the whole day or at intervals ranging from 15 to
20 min during the day and from 30 to 60 min at night. The
devices implemented an auscultatory algorithm (Accutracker II;
SunTech Medical Instruments, Raleigh, NC, USA) in Uppsala43
or an oscillometric technique (SpaceLabs 90202 and 90207
(Spacelabs Healthcare, Snoqualmie, WA, USA), Takeda
TM-2421 recorders (A&D, Tokyo, Japan) and Nippon Colin
ABPM-630 (Omron Colin, Tokyo, Japan)) in the other
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Fig. 2 Absolute 10 year risk of (a) cardiovascular mortality and (b)
stroke incidence in relation to the mean level of systolic blood pressure
(SBP) measured at home in the morning in 2421 participants.36 The
analyses were standardized to the distributions (mean or ratio) of sex,
age, body mass index, heart rate, smoking and drinking, total cholesterol,
diabetes mellitus, history of cardiovascular diseases and treatment with
antihypertensive drugs. In each panel, mean SBP along the x-axis covers
the 2.5th–97.5th percentile interval. Four continuous lines represent the
risk independently associated with variability independent of the mean
(VIM) equal to 3, 6, 9 and 12 units. P-values are for the independent
effect of SBP (PSBP) and VIM (PVIM); np and ne indicate the number of
participants at risk and the number of events, respectively. Reproduced
with permission from Asayama et al.36
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cohorts.44–50 When accounting for the daily pattern of activities
of the participants, we defined daytime as the interval ranging
from 1 000 to 2 000 h in Europeans44,45,48,49 and South
Americans,46 and from 0800 to 1 800 h in Asians;47,50 the
corresponding night-time intervals
ranged from 0000 to 0600 h and from
2 200 to 0400 h, respectively. Within
individual subjects, we weighted the
means of the ambulatory blood pressure
level by the interval between readings.
To quantify the nocturnal fall in blood
pressure, we computed the night-to-day blood pressure ratio from
the night-time and daytime blood pressures. During a median
follow up of 11.4 years, 785 deaths and 611 fatal and non-fatal
cardiovascular events occurred in 5645 IDACO participants
(mean age 53.0 years; 54.0% women).40 After accounting for
covariables and the night-to-day ratio of systolic pressure, the HR
of all-cause mortality was 1.32 (95% CI 1.09–1.59) in the top
decile of the systolic sleep–trough morning surge
(≥ 37.0 mmHg). For cardiovascular and non-cardiovascular
deaths, these HR were 1.18 (95% CI 0.87–1.61) and 1.42 (95%
CI 1.11–1.80), respectively. For all cardiovascular, cardiac,
coronary and cerebrovascular events, the HR in the top decile of
the systolic sleep–trough morning surge was 1.30 (95% CI 1.06–
1.60), 1.52 (95% CI 1.15–2.00), 1.45 (95% CI 1.04–2.03) and
0.95 (95% CI 0.68–1.32), respectively. Furthermore, only in the
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Fig. 3 Multivariable-adjusted hazard ratios (HR) and 95% confidence intervals (CI) for (a,c) all-cause mortality and (b,d) cardiovascular events by
ethnic- and sex-specific deciles of the sleep–trough (a,b) and pre-awakening (c,d) morning surge in systolic blood pressure (SBP) in 5645 subjects.40 The
HR expresses the risk in deciles compared with the average risk in the whole study population and was adjusted for cohort, sex, age, body mass index,
smoking and drinking, serum cholesterol, history of cardiovascular disease, diabetes mellitus, antihypertensive drug treatment, 24 h SBP and the systolic
night-to-day blood pressure ratio. The number of events and incidence rates (events per 1000 person-years) are also given for each decile. Reproduced
with permission from Li et al.40
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top decile group was the risk
significantly higher than the average risk
in the whole population, whereas in the
50th percentile group the risk was
significantly lower (by 35%; P < 0.01)
for all-cause mortality and for all
cardiovascular events (Fig. 3).40 In conclusion, an exaggerated
morning surge, exceeding the 90th percentile of the population,
significantly and independently predicted cardiovascular outcome
and may contribute to risk stratification by ambulatory blood
pressure monitoring.
Several studies have explored why the morning surge in blood
pressure is difficult to use to stratify risk in clinical practice.
First, using the morning surge in blood pressure requires multiple
blood pressure readings during sleep and during the pre-
awakening and awakening periods. Second, subjects have to
complete a diary during ambulatory blood pressure monitoring to
report the sleeping and awake periods. In our database, these two
issues eliminated 4 850 of 11 786 available subjects. Finally, in
older patients with isolated systolic hypertension,51 the morning
surge in blood pressure, irrespective of its definition, was poorly
reproducible. Nearly 30% of subjects changed their surge status
either in the short term (median 33 days) or in the long term
(median 10 months).51
Average real variability in ambulatory pressure
To address the prognostic value of short-term BPV, we assessed
BPV from the SD and ARV in 24 h ambulatory blood pressure
recordings in the IDACO study,11,40–42 specifically 8 938
participants (mean age 53.0 years; 46.8% women) who were
followed up for a median of 11.3 years.11 Participants with a
higher BPV were older, had higher blood pressure, were more
likely to be male and to have diabetes mellitus. Higher diastolic
ARV in 24 h ambulatory blood pressure recordings predicted
(P ≤ 0.03) total (HR 1.13; 95% CI 1.07–1.19) and cardiovascular
(HR 1.21; 95% CI 1.12–1.31) mortality and all types of fatal
combined with non-fatal end-points (HR ≥ 1.07), with the
exception of cardiac and coronary events (HR ≤ 1.02; P ≥ 0.58).
Higher systolic ARV in 24 h ambulatory blood pressure
recordings predicted (P < 0.05) total (HR 1.11; 95% CI 1.04–
1.18) and cardiovascular (HR 1.17; 95% CI 1.07–1.28) mortality
and all fatal combined with non-fatal end-points (HR ≥ 1.07),
with the exception of cardiac and coronary events (HR ≤ 1.03;
P ≥ 0.54). The SD predicted only total and cardiovascular
mortality. After accounting for the 24 h blood pressure level,
ARV in 24 h ambulatory blood pressure recordings added only
0.1% to the prediction of a cardiovascular event (Table 1).
Sensitivity analyses considering ethnicity, sex, age, previous
cardiovascular disease, antihypertensive treatment, number of
blood pressure readings per recording or the night-to-day blood
pressure ratio were confirmatory. Our report established that
short-term reading-to-reading BPV is an independent risk factor,
but moreover also highlighted that the level of the 24 h blood
pressure remains the primary blood pressure-related risk factor to
account for in clinical practice.
CONCLUSION
We assessed BPV derived from home visit,28 self-measured
home pressure37 and ambulatory monitoring.11,40 We estimated
BPV (VIM, MMD and ARV) and the morning surge in blood
pressure. None of these variability indices or morning surge in
blood pressure substantially refined risk profiling over and
beyond the blood pressure level. In risk stratification, clinicians
should concentrate on blood pressure level, the predominant risk
factor modifiable by lifestyle measures and antihypertensive drug
treatment.
Table 1 Risk of a composite cardiovascular event explained by Cox regression11
Model
Systolic blood pressure Diastolic blood pressure
2 Log likelihood P-value R2 (%) ratio 2 Log likelihood P-value R2 (%) ratio
Basic model* 10307.0 N/A 9.95 10307.0 N/A 9.95
+24 h blood pressure 10213.4 < 0.001 11.1 10258.2 < 0.001 10.6
+24 h blood pressure and ARV 10209.4 0.046 11.2 10250.6 0.006 10.7
*The basic Cox model was stratified for cohort and included sex, age, 24 h heart rate, body mass index, smoking and drinking, serum cholesterol,
history of cardiovascular disease, diabetes mellitus and treatment with antihypertensive drugs as covariables.
P values are for the improvement of the fit across nested models.
Reproduced with permission from Hansen et al.11
N/A, not applicable.
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